SCHEMBL10154037

SCHEMBL10154037

CNS(=O)(=O)c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.64
GAA P10253 1/20 0.64
CA2 P00918 14/20 0.61
CA12 O43570 11/20 0.61
CA1 P00915 11/20 0.61
CA9 Q16790 11/20 0.61
CA6 P23280 5/20 0.61
CA5A P35218 5/20 0.61
CA7 P43166 5/20 0.61
CA5B Q9Y2D0 5/20 0.61
CA4 P22748 4/20 0.61
CA14 Q9ULX7 4/20 0.61
CA3 P07451 3/20 0.61
CA13 Q8N1Q1 3/20 0.61
HTT P42858 2/20 0.59
LMNA P02545 1/20 0.59
ALDH1A1 P00352 2/20 0.57
USP2 O75604 1/20 0.52
TSHR P16473 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7629070 0.87 SMN1; SMN2 (0.80) SMN1; SMN2GAACA2CA12CA1
SCHEMBL687206 0.81 SMN1; SMN2 (0.64) SMN1; SMN2GAACA2CA12CA1
SCHEMBL31520571 0.81 SMN1; SMN2 (0.64) SMN1; SMN2GAACA2CA12CA1
SCHEMBL8080277 0.80 SMN1; SMN2 (0.70) SMN1; SMN2GAACA2CA12CA1
Hydrochloric Acid SCHEMBL5344901 0.79 SMN1; SMN2 (0.61) SMN1; SMN2GAACA2CA12CA1
SCHEMBL202948 0.79 CA2 (0.81) CA2CA12CA1CA9CA6
SCHEMBL31475667 0.79 CA2 (0.68) SMN1; SMN2CA2CA12CA1CA9
SCHEMBL7142664 0.79 CA2 (0.68) SMN1; SMN2CA2CA12CA1CA9
SCHEMBL30960 0.78 GAA (1.00) SMN1; SMN2GAACA2CA12CA1
SCHEMBL1804982 0.78 SMN1; SMN2 (0.67) SMN1; SMN2GAACA2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 CN disclosed
CN-109715629-B Aza-indazole compounds for use in tendon and/or ligament injuries 诺华股份有限公司 2022-04-12 CN disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA SMN1; SMN2 4237/4885GAA 3043/4885CA2 2309/4885
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 SMN1; SMN2 1776/4885GAA 2832/4885CA2 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.